Nuclear Medicine

BICL is involved in several oncology trials applying several nuclear medicine methods as an outcome measure including metastatic disease in prostate cancer using PSMA PET and other malignant disease using FDG-PET. In addition, BICL has in depth expertise in dosimetry for clinical trials.

Nuclear Medicine & Dosimetry Team

 

NUK 3 (2).JPG
NUK 2 (2).JPG
NUK 7.JPG
NUK 8.JPG
NUK 6.JPG
NUK 4 (1).JPG
NUK 5.JPG
NUK 1 (2).JPG
NUK 9.JPG
NUK 10.JPG